Is Barnes & Noble
The bookstore chain is spending at least $15.7 million to buy Fictionwise, the parent company of eReader.com and eBookwise.com. eReader bills itself as "the world's largest eBook store" while eBookwise markets a namesake e-book reading device.
Fictionwise is different from Amazon.com's
The real mystery here is where Barnes & Noble is heading with this.
"Barnes & Noble said it plans to use Fictionwise as part of its overall digital strategy, which includes the launch of an e-Bookstore later this year," it says in the press release.
Good luck with that, B&N.
The chain's allure in its superstore format is clear. It's an inviting place with cozy chairs and aromatic coffee. What makes the chain think it can stand out in cyberspace? Borders
Barnes & Noble is more prolific, of course. It also has had fair success with its online store and launched the Wikipedia-esque Quamut last year.
I still see the company tiptoeing quietly into this market. Digital delivery is a great idea for a long-distance merchant like Amazon, but the last thing Barnes & Noble wants to do is cannibalize sales by convincing booklovers to stay home.
This may not be a deal made reluctantly, but I'll call it a half-hearted one until I see Barnes & Noble truly throw its weight behind the e-book market. If the company's timetable is honest, I guess I only have to wait a few more months before reading that particular chapter.
For related Foolishness:
Stock news, financial commentary, and your daily dose of Foolishness: Get plugged in to The Motley Fool on Twitter!
Longtime Fool contributor Rick Munarriz bought his Kindle back in May. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. He does not own shares in any of the companies in this story. The Fool has a disclosure policy.
More from The Motley Fool
3 Great Reasons to Sell Barnes & Noble, Inc. Stock
The beleaguered bookseller continues to disappoint investors.
What Happened in the Stock Market Today
Stocks continued their strong start to 2018. Holiday sales at Barnes & Noble disappointed investors, though, and Momenta Pharmaceuticals reported a successful drug trial.
Why Barnes & Noble, Inc. Stock Plunged Today
The bookselling retail chain endured a difficult holiday season. Here's what investors need to know.